Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 115   

Articles published

NVO 48.92 -0.73 (-1.47%)
price chart
Novo Nordisk jumps 4.8% after Tresiba receives FDA approval Novo Nordisk jumps 4.8% after Tresiba receives FDA approval. 2:06 a.m. Sept. 28, 2015. - Sara Sjolin. Novo Nordisk diabetes drug Tresiba OK'd by FDA. 4:29 p.m. Sept. 25, 2015. - Novo Nordisk to build €70 million plant ...
Analyst's Report Recap: Novo Nordisk A/S
The shares of Novo Nordisk A/S (ADR) (NYSE:NVO) currently has mean rating of 1.00 while 1 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 0 recommended as “HOLD”.
Novo Nordisk Slumps 4% Pre-Bell – Cuts FY16 Operating Profit Growth Outlook ...
Novo Nordisk A/S (NVO) Stares Down 50-Day Moving Average
Denmark-based drugmaker Novo Nordisk A/S (ADR) (NYSE:NVO) is just one of several pharmaceutical stocks making moves today, after Merck & Co.
Hottest European Stocks Now: Unilever N.V. (UN), Novo Nordisk A/S (NVO ...  iStreetWire
Most Active Stocks in Focus: Novo Nordisk A/S (ADR) (NVO), Ingersoll-Rand PLC (IR)
The Company moved -3.97% down right now and is at $49.65. Stock is trading in the real-time trading session with the total volume of 1.52 million shares, as compared to its average volume of 1.26 million shares.
Fundamental and Technical Report on Novo Nordisk A/S (ADR) (NYSE:NVO)
Novo Nordisk A/S (ADR) (NYSE:NVO) (TREND ANALYSIS) shares were traded with thin volume. The stock closed last trading session at $52.93, down by -1.07%, with a volume of 1,085,472 shares against an average volume for the last 3 months of ...
Novo Nordisk A/S (ADR) (NYSE:NVO) on Watch List
[The Motley Fool] Novo Nordisk A/S (ADR) (NYSE:NVO)(TREND ANALYSIS) Diabetes powerhouse Novo Nordisk A/S (ADR) (NYSE:NVO) recently presented impressive data on its type 2 diabetes drug candidate IDegLira. IDegLira is an investigational ...
Novo Nordisk Up on Positive Results from Diabetes Study
Novo Nordisk A/S (ADR) Stock Surges On Increased Profit And Sales
Novo Nordisk A/S (ADR) (NYSE:NVO) announced its earnings for the first quarter of 2015 and the financial guidance for the full year 2015, and said that its current chief executive officer, Lars Rebien Sorensen, will remain at the helm of the company ...
Novo Nordisk CFO: U.S. Obesity Market Must Emerge, But It Will Take Time  Benzinga
Novo Nordisk profit rises; raises 2015 outlook  MarketWatch
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.